A randomized, double-blind, placebo-controlled trial of recombinant erythropietin in treatment of the anemia of bronchopulmonary dysplasia†
References (20)
- et al.
Effect of booster blood transfusions on oxygen utilization in infants with bronchopulmonary dysplasia
J Pediatr
(1988) - et al.
Evaluation of the mechanism causing anemia in infants with bronchopulmonary dysplasia
J Pediatr
(1992) - et al.
Recombinant erythropoietin compared to erythrocyte transfusion to treat the anemia of prematurity
J Pediatr
(1991) Radiographic aspects of bronchopulmonary dysplasia
J Pediatr
(1979)Anemia in the ICN graduate
The anemia of chronic disorders
Semin Hematol
(1973)- et al.
A randomized trial to develop criteria for administering erythrocyte transfusions to anemic preterm infants 1 to 3 months of age
J Perinatol
(1989) - et al.
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Pediatrics
(1980) - et al.
Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease
Pediatrics
(1992) - et al.
Portal venous aortic glucose and lactate changes in a chronically catheterized rat
Pediatr Res
(1988)
Cited by (22)
Developmental Erythropoiesis
2011, Fetal and Neonatal Physiology E-Book, Fourth EditionDevelopmental Erythropoiesis
2003, Fetal and Neonatal Physiology: Third EditionThe use of erythropoietin in neonates
2000, Clinics in PerinatologyCitation Excerpt :This anemia was initially described by Alverson et al3 and subsequently characterized by Christensen and colleagues17 as a normocytic, normochromic, hyporegenerative anemia with marrow normoblast iron stains that are distinct from those observed in the anemia of chronic disorders and the anemia of prematurity. Patients with the anemia of bronchopulmonary dysplasia treated with Epo had increased reticulocytes and hematocrits, and required fewer transfusions than placebo recipients.56 Factors that likely play a role in this anemia include inflammatory mediators, which create a relatively Epo-resistant environment, such as IL-1, tumor necrosis factor, interferon gamma,38 and common medications that have been associated with decreased Epo concentrations, such as methylzanthines and corticosteroids.5,25,62
The role of erythropoietin in the anemia of prematurity
1997, Seminars in Perinatology
- †
Supported by grants HD-00988, HL-44051, and RR-00064 from the National Institutes of Health and a grant from Primary Children's Medical Center Foundation.